Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ: NBIX )

109.07 +1.85 (+1.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,342,672
Open 108.45
Bid (Size) 106.02 (1)
Ask (Size) 121.00 (2)
Prev. Close 107.22
Today's Range 106.83 - 109.56
52wk Range 105.17 - 157.98
Shares Outstanding 99,400,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
NEUROCRINE BIOSCIENCES INC has a stellar value proposition. NASDAQ:NBIX not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point. 
Via Chartmill
NASDAQ:NBIX is showing decent growth, but is still valued reasonably.
NASDAQ:NBIX is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill

Performance

YTD
-20.88%
-20.88%
1 Month
-8.19%
-8.19%
3 Month
-14.94%
-14.94%
6 Month
-10.21%
-10.21%
1 Year
-20.81%
-20.81%

More News

Read More
Assessing Neurocrine Biosciences: Insights From 15 Financial Analysts
Via Benzinga
Why Neurocrine Biosciences Stock Sank Today
Via The Motley Fool
Estee Lauder, Moderna And PayPal Are Among Top 10 Large Cap Losers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?
Via Benzinga
Why the quality investor may take a look at NASDAQ:NBIX.
Via Chartmill
Earnings Summary: Neurocrine Biosciences Q4
Via Benzinga
Earnings Scheduled For February 6, 2025
Via Benzinga
Neurocrine Biosciences Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Via Benzinga
Why Is Neurocrine Biosciences Stock Trading Lower On Friday?
Via Benzinga
Neurocrine Biosciences Reports Mixed Q4
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug
Via Investor's Business Daily
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX.
Via Chartmill
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
Via Chartmill
NASDAQ:NBIX: good value for what you're paying.
Via Chartmill
What Analysts Are Saying About Neurocrine Biosciences Stock
Via Benzinga
NASDAQ:NBIX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights
Via Benzinga
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.
Via Chartmill
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Deserves Consideration as a Quality Investment.
Via Chartmill
Neurocrine Biosciences Stock Sees RS Rating Upgrade
Via Investor's Business Daily
While growth is established for NASDAQ:NBIX, the stock's valuation remains reasonable.
Via Chartmill
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
Via Benzinga
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
Via Benzinga
Exposures Product Safety
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.